Key consumer groups, pharmacy benefit managers, the insurance industry lobby and lawmakers from both parties blasted Mylan Pharmaceuticals for its newly unveiled patient assistance plan to reduce consumers' out-of-pocket costs for EpiPens, saying the move falls far short of what is needed to address growing criticism of the company's sharp price hike for the auto-injector product. Mylan announced Thursday (Aug. 25) it is reducing the auto-injector's cost through the use of a savings card that will cover up to $300...